Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAF156 prophylaxis in controlled human malaria challenge
NCT04072302Phase 1Completed
- Sponsor
- Novartis
- Start
- Sep 2014
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ganaplacide in malaria (12 arms), sponsored by Novartis. Primary endpoints: Number of subjects with parasitemia and Relationship between pharmacokinetics and number of subjects with parasitemia. Started Sep 2014; status: completed.
02
Drugs
ganaplacide
03
Conditions
malaria
Beyond the preview
Go deeper on NCT04072302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04072302.